Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Principal Financial Group Inc. lowered its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 7.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 787,484 shares of the company’s stock after selling 65,718 shares during the quarter. Principal Financial Group Inc. owned 1.37% of Structure Therapeutics worth $22,050,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in GPCR. State of Wyoming bought a new position in shares of Structure Therapeutics in the 2nd quarter valued at about $28,000. Assetmark Inc. lifted its stake in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after purchasing an additional 820 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after purchasing an additional 994 shares during the period. Raymond James Financial Inc. bought a new position in shares of Structure Therapeutics during the 2nd quarter valued at approximately $129,000. Finally, DNB Asset Management AS purchased a new stake in Structure Therapeutics during the 2nd quarter valued at $221,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $74.92 on Friday. The company has a market capitalization of $4.55 billion, a PE ratio of -61.41 and a beta of -2.06. The company has a 50 day moving average price of $70.81 and a 200-day moving average price of $41.23. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $13.22 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Analysts Set New Price Targets

GPCR has been the subject of several recent analyst reports. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. JPMorgan Chase & Co. upped their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Stifel Nicolaus increased their price objective on shares of Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. HC Wainwright boosted their target price on Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Citizens Jmp upped their target price on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a research note on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and an average target price of $104.45.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.